Segal Trials, a pioneering clinical research site network, is proud to announce its participation in this year’s CNS Summit that occurred in Boston, MA on November 8-11, 2023, a one of a kind event in the life sciences industry.
CNS Summit 2023 was an unparalleled gathering of industry leaders, providing a platform to discuss the latest advancements in the field and network with a curated community of visionaries. With a diverse array of sessions covering topics crucial to the life sciences industry, this is a “must-go-to” event for anyone invested in advancing medicine and driving positive change.
As a proud panelist in the Psychedelic Spotlight Session at the Summit, Dr. Rishi Kakar, Medical Director and CSO at Segal Trials, emphasized the importance of having the site’s voice heard, stating, “In the evolving landscape of CNS research, psychedelic studies have emerged as a promising frontier. At Segal Trials, we are dedicated to pushing the boundaries of scientific exploration and unlocking the potential of psychedelic treatments. Participating in CNS Summit 2023 allows us to share our insights and contribute to the global conversation on psychedelic research.”
Amir Kalali, Chief Curator and Chairman of CNS Summit, shared his mission behind the event, saying, “CNS Summit is a platform for collaboration, innovation, and transformative discussions that drive progress in the life sciences industry. We are thrilled to have Segal Trials as a long-standing partner and advocate for pioneering research.”
As one of the first private research sites to conduct psychedelic clinical studies in the US, Segal Trials continues to reinforce its position as a leading research site network.
For more information about Segal Trials and their participation in CNS Summit 2023, please visit www.SegalTrials.com
About Segal Trials:
Established in 1999, Segal Trials is a leading clinical research site network dedicated to advancing medical science and improving the lives of patients through high-quality research. With a focus on central nervous system disorders, women’s health and infectious disease, Segal Trials plays a pivotal role in shaping the future of medicine.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231201219064/en/
Contacts
Media Contact
Tabatha Cirgenski, Director of Marketing
Segal Trials
tcirgenski@segaltrials.com
305-722-8444
Source: Segal Trials
View this news release online at:
http://www.businesswire.com/news/home/20231201219064/en
